Instadose Pharma (Instadose Pharma) Change In Working Capital : $0.67 Mil (TTM As of Feb. 2022)

View and export this data going back to 2019. Start your Free Trial

What is Instadose Pharma Change In Working Capital?

Instadose Pharma's change in working capital for the quarter that ended in Feb. 2022 was $0.65 Mil.

Instadose Pharma's change in working capital for the fiscal year that ended in Nov. 2021 was $0.08 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Instadose Pharma Change In Working Capital Historical Data

The historical data trend for Instadose Pharma's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Instadose Pharma Change In Working Capital Chart

Instadose Pharma Annual Data

Trend

Nov16

Nov17

Nov18

Nov19

Nov20

Nov21

Change In Working Capital

Get a 7-Day Free Trial

0.08

Instadose Pharma Quarterly Data
	May17	Aug17	Nov17	Feb18	May18	Aug18	Nov18	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22
Change In Working Capital	Get a 7-Day Free Trial															0.06	-0.05	0.02	0.05	0.65

Instadose Pharma Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Feb. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.67 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Instadose Pharma Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Instadose Pharma's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Instadose Pharma (Instadose Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Instadose Pharma Corp (OTCPK:INSD) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

5500 North Service Road, Suite 301, Burlington, ON, CAN, L7L 6W6

Website

https://www.instadosepharma.com

Instadose Pharma Corp, formerly Mikrocoze Inc is seeking to create a global distribution platform for medicinal cannabis and cannabinoid oil. The company endeavors to utilize the Global Distribution Platform to open the commercial gateway to a new wholesale marketplace along with providing pharmaceutical industry companies with large, sustainable, consistent, diverse, and low?cost supplies of high?quality medicinal cannabis and cannabinoid oil for use in bulk as an active pharmaceutical ingredient.